Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study | Zendy

Ivana Pavik | Zendy; Philippe Jaeger | Zendy; Lena Ebner | Zendy; Carsten A. Wagner | Zendy; Katja Petzold | Zendy; Daniela Egli-Spichtig | Zendy; Diane Poster | Zendy; Rudolf P. Wüthrich | Zendy; Stefan Russmann | Zendy; Andreas L. Serra | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study

Author(s) -

Ivana Pavik,

Philippe Jaeger,

Lena Ebner,

Carsten A. Wagner,

Katja Petzold,

Daniela Egli-Spichtig,

Diane Poster,

Rudolf P. Wüthrich,

Stefan Russmann,

Andreas L. Serra

Publication year - 2012

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfs460

Subject(s) - klotho , medicine , kidney disease , endocrinology , fibroblast growth factor 23 , renal function , parathyroid hormone , calcitriol , vitamin d and neurology , vitamin d deficiency , calcium , kidney

Klotho and fibroblast growth factor 23 (FGF23) are key regulators of mineral metabolism in renal insufficiency. FGF23 levels have been shown to increase early in chronic kidney disease (CKD); however, the corresponding soluble Klotho levels at the different CKD stages are not known.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research